calcolinc
4 years ago
$CLCL Marijuana Stock GW Pharmaceuticals Delivers Rapid Growth In Q1
Demand for the marijuana drug developer's treatment for epilepsy caused shares to skyrocket last quarter.
Todd Campbell
Todd Campbell
(TMFEBCapital)
May 11, 2020 at 6:23PM
Author Bio
GW Pharmaceuticals (NASDAQ:GWPH) unveiled first-quarter financial results after the market closed on Monday, reporting revenue growth of 207% year over year to $120.6 million and a non-GAAP loss of $0.02 per share, which beat analysts expectations by $0.05 per share.
Surging demand for its marijuana treatment for epilepsy
The biotech company's revenue growth was due to surging sales of Epidiolex, a purified formulation of cannabidiol, or CBD, the second most common chemical cannabinoid found in marijuana. Growing use of Epidiolex by patients with the rare epilepsy disorders Dravet syndrome and Lennox-Gastaut syndrome resulted in net product sales of $116.1 million in the first quarter, including $106.1 million in U.S. revenue.
CBD oil being added to a prescription bottle with a dropper.
IMAGE SOURCE: GETTY IMAGES.
GW Pharmaceuticals remaining revenue came from Sativex, a THC-based drug approved in Europe for use in multiple sclerosis spasticity, or uncontrolled muscle spasms. Phase 3 studies of Sativex that could support a U.S. application for approval are expected to commence later this year.
The company's $8 million net loss in the quarter was a significant improvement from its $50 million loss in the same quarter last year, because operating expenses, including research and development costs, grew much more slowly than revenue. Overall, operating expenses increased 41% year-over-year to $127.8 million.
Epidiolex revenue could continue increasing this year following successful launches in Germany and the United Kingdom. GW Pharmaceuticals also says it plans to make Epidiolex available in France, Spain and Italy later this year, too.
Additionally, management expects a Food and Drug Administration decision to approve Epidiolex for use in tuberous sclerosis complex (TSC) on July 31. Last year, the company reported that Epidiolex's use reduced seizures caused by tumors in TSC patients by 48% in a phase 3 clinical trial. If approved, it could roughly double Epidiolex's addressable patient population.
Here's The Marijuana Stock You've Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming.
Cannabis legalization is sweeping over North America – 11 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.
And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.
Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks.
Simply click here to get the full story now.
Learn more
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
calcolinc
5 years ago
PepsiCo's energy drink move creates a buzz
Mar. 14, 2020 11:07 AMPepsiCo, Inc. (PEP)KO, MNSTBy: Clark Schultz, SA News Editor
PepsiCo (NASDAQ:PEP) made a rock star deal with the pickup of RockStar Energy, but the extra financial load has the food & beverage giant on a ratings watch "negative" at Moody's for a potential cut.
"Moody's expects PepsiCo's management to remain relatively conservative and to maintain modest leverage despite somewhat high shareholder returns. However, a key factor in the review will be the extent to which the company is willing to reduce shareholder returns to restore stronger credit metrics after this or future acquisitions," notes the ratings agency.
The view from sell-side firms after the energy drink deal was more positive. "With Rockstar underneath their wings, they'll have a family of energy drinks... they can coordinate the activity of an entire family of brands to meet a variety of needs of people," updated Edward Jones analyst John Boylan on the acquisition. UBS also broke down the energy drink market development. "This deal demonstrates PEP’s intention to become a bigger player in the high-growth, high-margin Energy Drink space. Beyond deploying resources to reinvigorate the Rockstar brand, the transaction opens the door to further expansion opportunities in the category including innovations behind the existing portfolio in addition to future partnerships and acquisitions," advised analyst Sean King.
Shares of PepsiCo have fallen off 13% over the last six weeks amid the coronavirus outbreak and concerns over the global economy. Late last week, analysts warned that a lack of social gatherings and sporting events is a short-term negative for PepsiCo sales. That would likely apply to energy drink players Coca-Cola (NYSE:KO) and Monster Beverage (NASDAQ:MNST) as well.
calcolinc
5 years ago
PepsiCo to buy Rockstar Energy for $3.8 billion
By Noah Manskar March 11, 2020 | 8:35am
Rockstar energy drinks
Shutterstock
PepsiCo has reached a deal to buy the Rockstar energy drink maker for $3.85 billion, the food and beverage giant said Wednesday.
The acquisition of Rockstar Energy Beverages — whose offerings include edgy-sounding flavors such as “Whipped Strawberry” and “Killer Grape” — aims to help Pepsi grow its presence in the energy drink market, the company said.
“Over time, we expect to capture our fair share of this fast-growing, highly profitable category and create meaningful new partnerships in the energy space,” PepsiCo chairman and CEO Ramon Laguarta said in a statement.
The deal, expected to close in the first half of this year, will expand Pepsi’s portfolio of energy drinks that already includes the Mountain Dew brand’s Kickstart, GameFuel and AMP offerings. The global energy drink market was valued at about $53 billion in 2018 and is expected to grow to roughly $86 billion by 2026, according to an Allied Market Research report.
MORE ON:
PEPSICO
Coffee-infused soda drives Coca-Cola revenue beat
PepsiCo stock rises after strong third-quarter earnings
PepsiCo will pay you to eat junk food with new cashback rewards
Mountain Dew apologizes to Michigan after embarrassing geography mistake
PepsiCo has distributed Rockstar drinks in North America since 2009. But the current distribution agreement puts limits on how Pepsi can work with other brands and what it can do with its own Mountain Dew energy drink brands, according to The Wall Street Journal, which first reported the acquisition.
“We have had a strong partnership with PepsiCo for the last decade, and I’m happy to take that to the next level and join forces as one company,” Rockstar founder Russ Weiner said in a statement. “PepsiCo shares our competitive spirit and will invest in growing our brand even further.”
PepsiCo said it doesn’t expect the Rockstar deal to materially affect its revenue or earnings per share this year. PepsiCo shares were down 0.5 percent in premarket trading at $133.40 as of 7:16 a.m.
calcolinc
5 years ago
Non – Alcoholic Beverage 3650 Market Growth Probability, Key Vendors and Future Scenario Up To 2024
July 10, 2019 No Comments Non - Alcoholic Beverage 3650 Market Research Report
The Non – Alcoholic Beverage 3650 Market report provides an unbiased and detailed analysis of the on-going trends, opportunities/ high growth areas, market drivers, which would help stakeholders to device and align Non – Alcoholic Beverage 3650 market strategies according to the current and future market The Non – Alcoholic Beverage 3650 Market report covers the Global market and regional market analysis. The Non – Alcoholic Beverage 3650 industry report examines, keep records and presents the worldwide market size of the important players in each region around the globe. Also, the report offers information of the leading market players in the Non – Alcoholic Beverage 3650 market.
Access Global Non – Alcoholic Beverage 3650 Market Research Report Details at: at https://www.pioneerreports.com/report/433285
About Non – Alcoholic Beverage 3650 Industry
–
The overviews, SWOT analysis and strategies of each vendor in the Non – Alcoholic Beverage 3650 market provide understanding about the market forces and how those can be exploited to create future opportunities.
Key Players in this Non – Alcoholic Beverage 3650 market are:–
Calcol Inc.
Danone
Nestle S.A.
PepsiCo Inc.
Monster Beverage Company
San Benedetto
Taisun Enterprise Co. Ltd.
Coca Cola Company
Dydo Drinco Inc.
Attitude Drinks
Berry Blendz
Hangzhou Wahaha Group
Request for Sample Copy of this Non – Alcoholic Beverage 3650 Market Report at https://www.pioneerreports.com/request-sample/433285
Production Analysis: SWOT analysis of major key players of Non – Alcoholic Beverage 3650 industry based on a Strengths, Weaknesses, company’s internal & external environments. …, Opportunities and Threats. . It also includes Production, Revenue, and average product price and market shares of key players. Those data are further drilled down with Manufacturing Base Distribution, Production Area and Product Type. Major points like Competitive Situation and Trends, Concentration Rate Mergers & Acquisitions, Expansion which are vital information to grow/establish a business is also provided.
Application of Non – Alcoholic Beverage 3650 Market are:
Speciality Stores
Online Store
Convinience Stores
Product Segment Analysis of the Non – Alcoholic Beverage 3650 Market is:
Carbonated drinks
Non-Carbonated
Look into Table of Content of Non – Alcoholic Beverage 3650 Market Report at https://www.pioneerreports.com/TOC/433285
Geographically this report covers all the major manufacturers from India, China, USA, UK, and Japan. The present, past and forecast overview of Non – Alcoholic Beverage 3650 market is represented in this report.
The report offers the market growth rate, size, and forecasts at the global level in addition as for the geographic areas: Latin America, Europe, Asia Pacific, North America, and Middle East & Africa. Also it analyses, roadways and provides the global market size of the main players in each region. Moreover, the report provides knowledge of the leading market players within the Non – Alcoholic Beverage 3650 market. The industry changing factors for the market segments are explored in this report. This analysis report covers the growth factors of the worldwide market based on end-users.
Inquire for further detailed information of Non – Alcoholic Beverage 3650 Market Report at: https://www.pioneerreports.com/pre-order/433285
Manufacturing Analysis Non – Alcoholic Beverage 3650 Market
Manufacturing process for the Non – Alcoholic Beverage 3650 is studied in this section. It includes through analysis of Key Raw Materials, Key Suppliers of Raw Materials, Price Trend of Key Raw Materials, cost of Raw Materials & Labor Cost, Manufacturing Process Analysis of Non – Alcoholic Beverage 3650 market
Marketing Strategy Analysis, Distributors/Traders Analysis of Non – Alcoholic Beverage 3650 Market
Various marketing channels like direct and indirect marketing are portrayed in Non – Alcoholic Beverage 3650 market report. Important marketing strategical data , Marketing Channel Development Trend, , Pricing Strategy, Market Positioning, Target Client Brand Strategy and Distributors/Traders List
In this study, the years considered to estimate the market size of Non – Alcoholic Beverage 3650 Market are as follows:-
History Year: 2013-2017
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2024
No Of Pages in Non – Alcoholic Beverage 3650 Market Report: 112
Single User Licence Price: USD
Purchase Report at https://www.pioneerreports.com/checkout/433285
Non – Alcoholic Beverage 3650 market reports deliver insight and expert analysis into key consumer trends and behaviour in marketplace, in addition to an overview of the market data and key brands. Non – Alcoholic Beverage 3650 market reports provides all data with easily digestible information to guide every businessman’s future innovation and move business forward.
calcolinc
5 years ago
Global Nonalcoholic Drinks Market 2019 Business Scenario – A.G. Barr, Dr. Pepper Snapple Group, Dydo Drinco, Attitude Drinks, Livewire Energy, Calcol etc. – World Analytics. https://worldanalytics24.com/global-nonalcoholic-drinks-market-2019-business-scenario-a-g-barr-dr-pepper-snapple-group-dydo-drinco-attitude-drinks-livewire-energy-calcol-etc/380293/
calcolinc
5 years ago
Please visit our 3 websites on Facebook, our two Twitter accounts, our Company description on otcmarkets.com, and you are most welcome to buy our products either wholesale or retail. A simple google search of images will show you photos of our American made products for sale. Our CEO’s bio (verified) is printed in many editions of Marquis Who’s Who in America, Who’s Who in Asia, and Who’s Who in the World, which can be found at any library and online.Thanks! CALCOL INC. (CLCL-OTC)
calcolinc
5 years ago
Please visit our 3 websites on Facebook, our two Twitter accounts, our Company description on otcmarkets.com, and you are most welcome to buy our products either wholesale or retail. A simple google search of images will show you photos of our American made products for sale. Our CEO’s bio (verified) is printed in many editions of Marquis Who’s Who in America, Who’s Who in Asia, and Who’s Who in the World, which can be found at any library and online.Thanks! CALCOL INC. (CLCL-OTC)
calcolinc
5 years ago
ONE MORE STEP FOR MEDICINAL MARIJUANA NY TIMES NORMAN C KAPLAN
SEPT. 6, 1983
As printed in the New York Times and cited in the US Congressional Record by Congressman Louis Stokes (D21-Ohio) in 1983:
NY TIMES Archives | 1983
ONE MORE STEP FOR MEDICINAL MARIJUANA
SEPT. 6, 1983
About the Archive
This is a digitized version of an article from The Times’s print archive, before the start of online publication in 1996. To preserve these articles as they originally appeared, The Times does not alter, edit or update them.
To the Editor:
As a cancer researcher who has worked with the marijuana derivative Delta-9-Tetrahydrocannabinol for the past five years, both in its anti- cancer properties and in its anti-nausea properties for patients receiving cancer chemotherapy, I applaud your Aug. 27 editorial ''Marijuana and Medicine.''
A recent computer search of the medical literature revealed that over 50 articles on the therapeutic uses of the derivative and its analogues were published in the last three years. I have often commented on the tragic circumstances that in the past allowed this drug with tremendous medical potential to be readily available illegally to the individual on the street while it was difficult, nigh impossible, for the person suffering the ravages of cancer and chemotherapy to obtain.
Nevertheless, both the National Cancer Institute and the National Institute on Drug Abuse have made every effort in recent years to make Delta-9-Tetrahydrocannabinol capsules (Schedule I) available free to those suffering with cancer, and to make it available to researchers like myself working with scientific protocols acceptable to research committees within the state and Federal establishment. What is needed, as you state, is for the Food and Drug Administration and the Drug Enforcement Administration, under the urging of Congress, the scientific and medical community and the public, to move therapeutic Delta-9-Tetrahydrocannabinol from Schedule I (Investigational Experimental Substance) to Schedule II (Controlled Narcotic), which would enable any licensed oncologist, surgeon, opthalmologist, psychiatrist or other physician to prescribe it without excessive regulation or fear of legal liability for use of an ''experimental'' pharmaceutical. For responsible medical researchers, the substance has been and remains available; the problem is to ease the bureaucratic tangle that makes it difficult for physicians to order it and supply it to their patients. NORMAN CHARLES KAPLAN Shaker Heights, Ohio, Aug. 27, 1983
The writer is president of Calcol Inc., a medical and scientific research and consulting firm.
????? ????
??.???
NORMAN C KAPLAN
(CALCOL INC.(CLCL-OTC)
MALIBU-COLA BEVERAGE CO. LTD.
BEIJING KULONG ENERGY TRADING CO. LTD.
KULONG ENERGY BEVERAGE COMPANY INC.
FACEBOOK: NORMAN KAPLAN, CALCOL INC.,KULONG ENERGY BEVERAGE
COMPANY INC.
PO BOX 22228
BEACHWOOD OHIO 44122
calcolinc
5 years ago
$CLCL Please visit our three websites on Facebook, fb.me/calcolinc, fb.me/kulongenergy, fb.me/normankaplan, and two Twitter accounts KULONG ENERGY DRINK @EnergyKulong, and CALCOL @normankaplan14, and the Company description on otcmarkets.com.This is not an offer to buy or sell securities. CALCOL INC. common stock involves a high degree of risk and is a suitable investment only for accredited high net worth investors,
Institutional investors and overseas investors who are able to assess the risk and can afford to lose their entire investment. Please consult a licensed stockbroker or investment advisor at etrade, TD Ameritrade, Charles Schwab, Merrill Lynch or a similar member firm before making any investment decision. Thanks!
News
Market Data
Register to chat with like-minded investors on our interactive forums.
StockHighAlert-
5 years ago
Quintessence
5 years ago
